A high pretreatment systemic immune-inflammation index level is associated with worse survival outcomes in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors, according to a recent study. A team from the Peking Union Medical College and Chinese Academy of Medical Sciences conducted the study and published their findings in Critical Reviews in Oncology/Hematology. ...
Immunotherapy in Non-Small Cell Lung Cancer
Advertisement
The therapy is currently under evaluation in phase 1 and phase 2 trials.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.